Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital ...( LOS GATOS Calif. Dec. 16 /- a href ht...),Health

LOS GATOS, Calif., Dec. 16 /PRNewswire/ -- TriCipher will host an informative Webinar detailing the cost cutting capabilities of digital signatures for the pharmaceutical and health care industries and strategies for securing digital signatures as more business processes transition online. The one hour webinar on December 16th brings together executives from SAFE- BioPharma Association and Pfizer who will discuss how digital signatures have benefited and streamlined research processes.

"Digital signatures represent the 'last mile' in moving business processes online for the pharmaceutical and health care industries," said Jon Brody, vice president of marketing at TriCipher. "Through the work of industry associations like SAFE-BioPharma and enabling technology companies like TriCipher, it's now possible to bridge that gap."

    Participants that attend the Webinar will learn:

     --   How businesses have saved hundreds of thousands of dollars by no
          longer needing to handle paper-based signatures
     --   The benefits of streamlining submissions to FDA and other regulatory
          agencies
     --   Strategies for protecting intellectual property and delivering a
          long term solution to IP preservation
     --   The 'Green' benefits of digital signatures


     WHO:      Mollie Shields-Uehling, president and CEO, SAFE-BioPharma
               Association
               William Barnes, Director of Identity Services, Pfizer
               Jon Brody, vice president of marketing, TriCipher
               A managing director of identity services at a leading
               international systems integrator
     WHAT:     "Cutting Costs with Digital Signatures in the Biopharmaceutical
               Industry"
     WHEN:     Tuesday, December 16th, 11 a.m. - 12 p.m. PT
     WHERE:    To register please visit:
              
SOURCE  TriCipher, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 
Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance